Keith Ferdinand, MD
Cardiovascular Disease · New Orleans, LANPI 1851398622
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $146,319 of the $238,840 with a category attached, or 61.3%. It is spread thinly across 29 manufacturers, the largest accounting for just 21.0%. Reporting peaked in 2023 at $49,870 and has fallen 81.7% since, to $9,111 in 2025. Among cardiovascular disease clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 287 payments — averaging $832.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$50K
- Novartis$33K
- Boehringer Ingelheim$31K
- Janssen Scientific Affairs, LLC$19K
- Johnson & Johnson$13K
- Eli Lilly$13K
- plus $80K from 23 others
Across 23 payments — averaging $4557.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$100K
- Boehringer Ingelheim International GmbH$2K
- Amgen$1K
- Regeneron$1K
What the payments were for
- Consulting fees$146,31961%
- Speaking & faculty fees$68,99529%
- Travel & lodging$16,8237%
- Food & beverage$6,4063%
- Education$2970%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 44 | $50,116 |
| Novartis | 22 | $32,941 |
| Boehringer Ingelheim | 17 | $31,212 |
| Janssen Scientific Affairs, LLC | 11 | $18,918 |
| Johnson & Johnson | 30 | $13,073 |
| Eli Lilly | 15 | $13,004 |
| Alnylam Pharmaceuticals Inc. | 8 | $11,707 |
| Amgen | 29 | $10,728 |
| Pfizer | 16 | $10,635 |
| AstraZeneca | 20 | $9,718 |
| Lilly USA, LLC | 2 | $9,300 |
| Novo Nordisk | 28 | $9,044 |
| Sanofi-aventis U.S. LLC | 7 | $7,449 |
| Sanofi Pasteur Inc. | 2 | $5,352 |
| Janssen Global Services, LLC | 1 | $2,790 |
| Biosense Webster, Inc. | 2 | $1,625 |
| Esperion Therapeutics, Inc. | 9 | $564 |
| Boston Scientific | 3 | $132 |
| Merck | 3 | $111 |
| Regeneron Healthcare Solutions, Inc. | 4 | $91 |
| E.r. Squibb & Sons, L.L.C. | 4 | $89 |
| Baxter Healthcare | 1 | $43 |
| Actelion Pharmaceuticals US, Inc. | 2 | $43 |
| Akcea Therapeutics, Inc. | 1 | $36 |
| Lexicon Pharmaceuticals, Inc. | 1 | $32 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $29 |
| Invivyd Inc | 1 | $24 |
| Atricure, Inc. | 1 | $20 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$238,840 in reported general payments places this provider in the 95th percentile of 281 cardiovascular disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 23 | $20,125 |
| Repatha SureclickEvolocumab | 14 | $18,282 |
| JardianceEmpagliflozin | 14 | $9,436 |
| JanuviaSitagliptin Phosphate | 12 | $7,053 |
| Nitroglycerin | 17 | $2,100 |
| Warfarin Sodium | 93 | $940 |
| Atorvastatin Calcium | 67 | $879 |
| Metoprolol Succinate | 70 | $679 |
| Ezetimibe | 36 | $655 |
| Rosuvastatin Calcium | 38 | $300 |
| Spironolactone | 34 | $277 |
| Amlodipine Besylate | 41 | $207 |
| Carvedilol | 22 | $199 |
| Potassium Chloride | 14 | $187 |
| ClopidogrelClopidogrel Bisulfate | 15 | $128 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $10,635 | $20,12523 claims |
| Boehringer IngelheimJardiance | $31,212 | $9,43614 claims |
| MerckJanuvia | $111 | $7,05312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 281 cardiovascular disease providers in Louisiana.
Other cardiovascular disease in New Orleans
- Carl LavieNew Orleans$228K
- Alexandra SanchezNew Orleans$69K
- Nabeel SaghirNew Orleans$49K
- Aimee HiltboldNew Orleans$29K
- Richard MilaniNew Orleans$28K
- Salima QamruddinNew Orleans$27K
- Joseph EnglertNew Orleans$19K
- Emmett ChapitalNew Orleans$13K
- Yvonne GillilandNew Orleans$13K
- Frank WilklowNew Orleans$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.